Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > COLUMN
COLUMN
- Maurer's Healthcare Insight (54)
May 17, 2004
- Maurer's Healthcare Insight (53)
April 19, 2004
- Maurer's Healthcare Insight (52)
March 22, 2004
- Maurer's Healthcare Insight (51)
March 1, 2004
- Maurer's Healthcare Insight (50)
February 16, 2004
- Maurer's Healthcare Insight (49)
January 26, 2004
- Maurer's Healthcare Insight (48)
December 1, 2003
- Maurer's Healthcare Insight (47)
November 3, 2003
- Maurer's Healthcare Insight (46)
October 6, 2003
- Maurer's Healthcare Insight (45)
September 8, 2003
- Maurer's Healthcare Insight (44)
August 11, 2003
- Maurer's Healthcare Insight (43)
July 14, 2003
- Maurer's Healthcare Insight (42)
June 16, 2003
- Maurer's Healthcare Insight (41)
May 19, 2003
- Maurer's Healthcare Insight (40)
April 28, 2003
- Maurer's Healthcare Insight (39)
April 14, 2003
- Maurer's Healthcare Insight (Special)
March 24, 2003
- Maurer's Healthcare Insight (Special)
March 17, 2003
- Maurer's Healthcare Insight (38)
February 17, 2003
- Maurer's Healthcare Insight (37)
January 20, 2003
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…